Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results
Ho Kim, Young, Ye, Byong Duk, Pesegova, Marina, Alexeeva, Olga, Osipenko, Marina, Lahat, Adi, Dorofeyev, Andrey, Salamon, Agnes, Fishman, Sigal, Levchenko, Olena, Cheon, Jae Hee, Scribano, Maria L., MVolume:
152
Language:
english
Journal:
Gastroenterology
DOI:
10.1016/s0016-5085(17)30571-1
Date:
April, 2017
File:
PDF, 618 KB
english, 2017